Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

STI 571 inhibition effect on KITAsn822Lys-mediated signal transduction cascade.

Experimental hematology - 1 Jun 2005

Beghini Alessandro, Bellini Melissa, Magnani Ivana, Colapietro Patrizia, Cairoli Roberto, Morra Enrica, Larizza Lidia

Abstract excerpt

OBJECTIVE: Alterations in growth factor signaling pathways may be a frequent collaborating event in AML1-ETO-mediated leukemogenesis. Gain-of-function KIT receptor mutations have been reported in adult AML patients, especially those with core binding factor leukemia (CBFL). We have previously reported a new gain-of-function KIT(Asn822Lys) mutation that is constitutively expressed in the Kasumi-1 CBFL cell line,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Asparagine

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Benzamides

Share to Imatinib Mesylate

Share to Lysine

Share to Piperazines

Share to Proto-Oncogene Proteins c-kit

Share to Pyrimidines

Source

Identifiers

PMID: 15911092
DOI: 10.1016/j.exphem.2005.03.007

Genes

KIT
STAT3

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

STI 571 inhibition effect on KITAsn822Lys-mediated signal transduction cascade.PMID 15911092Read ↗

STI571 inactivation of the gastrointestinal stromal tumor c-KIT oncoprotein: biological and clinical implications.Semantic proximity Read ↗

The Kasumi-1 cell line: a t(8;21)-kit mutant model for acute myeloid leukemia.Semantic proximity Read ↗

Inhibition of KIT tyrosine kinase activity: a novel molecular approach to the treatment of KIT-positive malignancies.Semantic proximity Read ↗

Constitutive activation of c-kit by the juxtamembrane but not the catalytic domain mutations is inhibited selectively by tyrosine kinase inhibitors STI571 and AG1296.Semantic proximity Read ↗

[STI571: a summary of targeted therapy].Semantic proximity Read ↗

Targeting c-Kit mutations: basic science to novel therapies.Semantic proximity Read ↗

Juxtamembrane mutant V560GKit is more sensitive to Imatinib (STI571) compared with wild-type c-kit whereas the kinase domain mutant D816VKit is resistant.Semantic proximity Read ↗

Effect of tyrosine kinase inhibitor STI571 on the kinase activity of wild-type and various mutated c-kit receptors found in mast cell neoplasmsSemantic proximity Read ↗

BPR1J373, an Oral Multiple Tyrosine Kinase Inhibitor, Targets c-KIT for the Treatment of c-KIT-Driven Myeloid Leukemia.Semantic proximity Read ↗

Extracellular KIT receptor mutants, commonly found in core binding factor AML, are constitutively active and respond to imatinib mesylate.Semantic proximity Read ↗

Resistance to c-KIT kinase inhibitors conferred by V654A mutation.Semantic proximity Read ↗

PU.1 and MYC transcriptional network defines synergistic drug responses to KIT and LSD1 inhibition in acute myeloid leukemiaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.